March 2020
Personalized Medicine in the Aftermath of COVID-19
Quick takes: Q&A with Jeff Evelhoch on Imaging Biomarkers for Alzheimer’s Disease
Something to Smile About: The Journey Toward a Cure with Rare Disease Foundation NFED
How Harvard Business School is Accelerating Precision Medicine
Quick takes: Q&A with Steve Anderson on bringing biomarkers from development to market
The Data-Powered Patient: Precision Medicine Enabled by Decentralized Identity and Blockchain
NC Creates Foundational Precision Health Initiative, Sara Imhof, Senior Director, Precision Health
North Carolina: a Global Life Science Leader, Sara Imhof, Senior Director, Precision Health
Best Practices for NGS-Based Cancer Diagnostics
Personalization and standardization: Can we have it all? What other industries can teach healthcare
Activating Patients: The Path to Personalizing Cancer Treatment
The Licensing Conundrum: How Licensing Can Facilitate (or Impede) Access to Research Models
Majors, Organizational Legitimacy and Rents from Blockbuster Innovation in the Biopharma Industry
DECEMBER 2019
A Case Study of Europe and Beyond
Fighting for Their Lives – The Battle of the BPAN Warriors
BPAN Warriors: A Rare Disease Community’s Search for Connection, Collaboration and a Cure
Special Report: The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments
Maximize healthcare performance by reducing unwarranted variations
Proteins: Life’s Simple Measures
Potential Impact of the VALID Act on IVD Manufacturers
Informatics Initiatives Exceed Value Expectations
The Future of Diagnostics in Precision Medicine
How Data and Informatics Intersect to Enable Precision Medicine to Reach its Full Potential
SEPTEMBER 2019
Shadow of the Future: Precision Medicine in Multiple Myeloma
Precision prescribing with pharmacogenomics
Personalized Medicine’s Path to Patients
Precision medicine approaches in sickle cell disease
Smarter, Accessible Data Means Learning from Every Patient
Informatics Approach and Considerations that Enable Precision Medicine Program Success
Women Leaders in Healthcare: Benefits of Diversity within Precision Medical Leadership
JUNE 2019
Rethinking patient education in oncology in the age of precision medicine
The current state of molecular testing
Opportunities to Advance Precision Medicine with Blockchain Powered AI
Is your organization “precision-medicine workforce ready”?
Raising the Bar: FDA Accelerates the Push Toward Personalized Medicine
MARCH 2019
Will DAIA resolve the ambiguities of regulating in vitro clinical tests?
Are your Companion Diagnostic Partners Ready?
Why Diagnostics Have Trouble Finding Their Voice
Immunothrapy: Predicting response to targeted therapies and checkpoint inhibitors
The Dawn of Personalized Medicine: The Role of the Pharmacist
Preventative medicine: genetic screening of inherited diseases
OCTOBER 2018
Direct-to-Consumer Genetic Testing is Disrupting Our Healthcare System by Empowering Consumers.
An Unlikely Alliance – Could PBMs and diagnosis labs find synergies in the healthcare market?
The Challenges of Patenting Precision Medicine in the Era of Mayo and Myriad
Takeda using Advanced Machine Learning to find insights about NASH & TRD
Enabling Genomics – Guided Precision Medicine with Real World Evidence
Neurodegenerative diseases and the microbiome: lessons learned from mouse models
Tweets
New post: Bristol Myers Squibb Receives European Commission Approval for Zeposia (ozanimod) for the Treatment of https://t.co/PjLpfjlnNI, - New post: Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA https://t.co/uvZsXDUAP2,
- New post: Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent reduced the risk https://t.co/rd1StAFQNs,
